Clinical research exploring whether a common nutrient might influence treatment approaches for an aggressive brain tumor, and potential implications for patients.
Key Takeaways
- Phase I-II trial tested high-dose niacin in newly diagnosed glioblastoma patients
- Niacin appeared to revive immune cells that tumors had shut down
- Early results showed significantly improved progression-free survival compared to expectations